Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Declines By 97.9%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totalling 150,000 shares, a decrease of 97.9% from the December 31st total of 7,300,000 shares. Based on an average daily volume of 906,000 shares, the short-interest ratio is presently 0.2 days. Currently, 16.5% of the company’s stock are sold short.

Insider Activity at CERo Therapeutics

In other CERo Therapeutics news, major shareholder Bioventures Opportunities G. Yk sold 12,368 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.00, for a total value of $148,416.00. Following the sale, the insider now owns 213,839 shares in the company, valued at $2,566,068. This represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders sold 64,300 shares of company stock valued at $529,409. Insiders own 18.00% of the company’s stock.

CERo Therapeutics Price Performance

NASDAQ:CERO remained flat at $1.87 on Tuesday. The company’s stock had a trading volume of 236,907 shares, compared to its average volume of 1,123,238. CERo Therapeutics has a 12-month low of $1.76 and a 12-month high of $1,280.00. The firm has a 50 day moving average of $9.38 and a two-hundred day moving average of $11.68.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.